Evidence map›Paper›PMID 41018776›Full record

ArticleFrontiers in public health2025

Taking the Translational Science Benefits Model from concept to operationalization: opportunities and challenges in defining impact using the Translational Science Benefits Model.

Jessica Sperling, Eman Ghanem, Stella Quenstedt, Tarun Saxena

Abstract read
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jessica SperlingClinical and Translational Science Institute, Duke University School of Medicine, Durham, NC, United States.
Eman GhanemClinical and Translational Science Institute, Duke University School of Medicine, Durham, NC, United States.
Stella QuenstedtClinical and Translational Science Institute, Duke University School of Medicine, Durham, NC, United States.
Tarun SaxenaClinical and Translational Science Institute, Duke University School of Medicine, Durham, NC, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Translational Science Benefits Model (TSBM) was developed to conceptualize and communicate the benefits and impact of translational research. While the TSBM was developed as a conceptual model rather than an operational process, it can be integrated into operational processes to provide evidence and clearly explain the impact of translational research and translational science. This paper discusses the use of the TSBM not only as a conceptual framework but also as a program-integrated operational mechanism. First, it discusses three TSBM-informed programmatic processes for addressing intended and achieved impact: case studies, Pilots program reporting, and an organizational database. Then, it outlines the key factors emerging from these processes that should be considered before employing TSBM as an integrated structure for collecting information on translational research outcomes. In particular, this paper discusses key

Indexed as

Models, TheoreticalTranslational Research, BiomedicalTranslational Science, BiomedicalHumansProgram Evaluationevaluationresearch operationsscientific impacttranslational researchtranslational scienceTranslational Science Benefits Model (TSBM)

Identifiers

PMID41018776
PMCPMC12463953

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.